Overview

Trial of NanoPac Intratumoral Injection in Lung Cancer

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
NanOlogy, LLC
Collaborator:
US Biotest, Inc.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel